ATLANTA, GA--(Marketwired - January 28, 2014) - GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.

The roundtable session was titled, "Which emerging technologies and scientific approaches do vaccine industry decision-makers and funders alike favor?" Dr. Robinson presented characteristics that distinguish neutralizing and protective non-neutralizing antibody for HIV. She also highlighted immunogen design for eliciting protective non-neutralizing antibody and the promise of non-neutralizing antibody for prevention of HIV.

"The concept of protective non-neutralizing antibody is important for HIV vaccines," said Dr. Robinson. "In contrast to neutralizing antibody, that vaccines have failed to elicit, protective non-neutralizing antibody can be elicited by vaccines, and may be particularly effectively elicited by vaccines that display the HIV envelope glycoprotein on virus-like particles -- such as those expressed by the GeoVax GOVX-B11 HIV vaccine."

The Phacilitate Vaccine Forum 2014 is part of the Washington BioLeaders Forum 2014, with an estimated attendance of 500-600 executives from pharma, biotech and key external stakeholders, including regulators, public and private sector investors, NGOs, payers and analysts.

About GeoVax

GeoVax is a biotechnology company developing vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax's unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. GeoVax has two vaccines undergoing development: GOVX-B11 and GOVX-B21. Both are for the clade B virus that is prevalent in the developed world. In both, the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GOVX-B21 differs from GOVX-B11 in co-expressing the genetic adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) with VLPs in the DNA prime. GeoVax's vaccines are currently being tested in human clinical trials, for both preventive and therapeutic applications. Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). GOVX-B11 has been evaluated in various doses and combinations in over 400 humans and is the company's lead product for a preventive vaccine. GOVX-B21 has been evaluated in 40 people in a phase 1 dose escalation and regimen trial.

About HIV/AIDS

HIV can infect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be over 2 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 10 1/2 minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in the Americas, Europe, and Australia. Globally, most infections involve Clades AG, B, and C. GeoVax's most advanced vaccines under development are designed to function against Clade B.

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.